Esomeprazol SUN Pharma 40 mg Pulver till injektions-/infusionsvätska, lösning Suécia - sueco - Läkemedelsverket (Medical Products Agency)

esomeprazol sun pharma 40 mg pulver till injektions-/infusionsvätska, lösning

sun pharmaceutical industries europe b.v. - esomeprazolnatrium - pulver till injektions-/infusionsvätska, lösning - 40 mg - esomeprazolnatrium 42,5 mg aktiv substans

Cilostazol EQL Pharma 100 mg Tablett Suécia - sueco - Läkemedelsverket (Medical Products Agency)

cilostazol eql pharma 100 mg tablett

eql pharma ab - cilostazol - tablett - 100 mg - cilostazol 100 mg aktiv substans - exkl. heparin

Prednisolon EQL Pharma 5 mg Tablett Suécia - sueco - Läkemedelsverket (Medical Products Agency)

prednisolon eql pharma 5 mg tablett

eql pharma ab - prednisolon - tablett - 5 mg - laktosmonohydrat hjälpämne; prednisolon 5 mg aktiv substans

Clindamycin EQL Pharma 150 mg Kapsel, hård Suécia - sueco - Läkemedelsverket (Medical Products Agency)

clindamycin eql pharma 150 mg kapsel, hård

eql pharma ab - klindamycinhydroklorid - kapsel, hård - 150 mg - klindamycinhydroklorid 162,88 mg aktiv substans; laktosmonohydrat hjälpämne

Clindamycin EQL Pharma 300 mg Kapsel, hård Suécia - sueco - Läkemedelsverket (Medical Products Agency)

clindamycin eql pharma 300 mg kapsel, hård

eql pharma ab - klindamycinhydroklorid - kapsel, hård - 300 mg - laktosmonohydrat hjälpämne; klindamycinhydroklorid 325,8 mg aktiv substans

Ribavirin Teva Pharma B.V. União Europeia - sueco - EMA (European Medicines Agency)

ribavirin teva pharma b.v.

teva b.v. - ribavirin - hepatit c, kronisk - antivirala medel för systemisk användning - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 och 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 och 5.

Dasatinib Accordpharma União Europeia - sueco - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Carbamazepine Essential Pharma 125 mg Suppositorium Suécia - sueco - Läkemedelsverket (Medical Products Agency)

carbamazepine essential pharma 125 mg suppositorium

essential pharma (m) ltd - karbamazepin - suppositorium - 125 mg - karbamazepin 125 mg aktiv substans - karbamazepin

Carbamazepine Essential Pharma 250 mg Suppositorium Suécia - sueco - Läkemedelsverket (Medical Products Agency)

carbamazepine essential pharma 250 mg suppositorium

essential pharma (m) ltd - karbamazepin - suppositorium - 250 mg - karbamazepin 250 mg aktiv substans - karbamazepin

Tetracyklin RPH Pharma 250 mg Tablett Suécia - sueco - Läkemedelsverket (Medical Products Agency)

tetracyklin rph pharma 250 mg tablett

rph pharmaceuticals ab - tetracyklinhydroklorid - tablett - 250 mg - sackaros hjälpämne; tetracyklinhydroklorid 250 mg aktiv substans; laktosmonohydrat hjälpämne - tetracyklin